10 01, 2024

Baby Powder Lawsuits Hurt JNJ while Closing Several Acquisitions; Down 11% in 2023, Is it a Sell?

By |2024-01-10T19:20:12+00:00January 10th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stocks in the News|Tags: , , , , , |

Johnson & Johnson (JNJ) is known for baby products and the single-shot COVID-19 vaccine, making it a significant booster if you invested before the pandemic. However, following recent lawsuits, JNJ settled to pay $700 million following an investigation over its baby powder, while the COVID-19 vaccine was discontinued in the US, leading to an [...]

17 10, 2023

Johnson & Johnson Beats Earnings & Raises Forecast – So Why is the Stock Falling?

By |2023-12-07T19:49:36+00:00October 17th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stocks in the News|Tags: , , , , , |

Yesterday, we highlighted Pfizer’s challenges in pivoting as a post-pandemic company. Today, its competitor Johnson & Johnson (JNJ) reported earnings itself.  But, Johnson & Johnson painted an entirely different picture - beating out the earnings estimate on the top and bottom line while raising the forecast for the remainder of the year. The company [...]

20 07, 2023

Johnson & Johnson Jumps 6% on Earnings Beat and Revised Guidance: Does it Deserve a Buy?

By |2023-12-07T20:46:04+00:00July 20th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stocks in the News|Tags: , , , |

Johnson & Johnson (JNJ) has had its ups and downs over the past few months, but it appears as if steady growth is ahead. The company has boosted its previous guidance for the year after Thursday’s earnings report came in well above analyst expectations. Johnson & Johnson saw sales growth of 6.3% for the [...]

Go to Top